Assetmark, Inc Vertex Pharmaceuticals Inc Transaction History

Assetmark, Inc

$36.2 Billion
Q1 2025

A detailed history of Assetmark, Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Assetmark, Inc holds 85,297 shares of VRTX stock, worth $38.5 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

85,297

Previous 79,865 6.8%

Holding current value

$38.5 Million

Previous $32.2 Million 28.58%

% of portfolio

0.11%

Previous 0.09%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 06, 2025	BUY	$402.49 - $513.76 $2.19 Million - $2.79 Million	5,432 Added 6.8%	85,297 $41.4 Million
Q4 2024 Feb 06, 2025	SELL	$396.64 - $516.74 $49.3 Million - $64.2 Million	-124,206 Reduced 60.86%	79,865 $32.2 Million
Q3 2024 Nov 01, 2024	SELL	$460.0 - $505.78 $81.1 Million - $89.2 Million	-176,283 Reduced 46.35%	204,071 $94.9 Million
Q2 2024 Aug 13, 2024	SELL	$392.81 - $485.53 $827,650 - $1.02 Million	-2,107 Reduced 0.55%	380,354 $178 Million
Q1 2024 May 06, 2024	SELL	$407.69 - $446.08 $2.01 Million - $2.2 Million	-4,937 Reduced 1.27%	382,461 $160 Million
Q4 2023 Feb 09, 2024	SELL	$343.0 - $410.68 $40.1 Million - $48.1 Million	-117,030 Reduced 23.2%	387,398 $158 Million
Q3 2023 Oct 27, 2023	SELL	$338.18 - $362.46 $2.28 Million - $2.44 Million	-6,743 Reduced 1.32%	504,428 $175 Million
Q2 2023 Aug 11, 2023	SELL	$314.42 - $351.91 $8.7 Million - $9.74 Million	-27,668 Reduced 5.13%	511,171 $180 Million
Q1 2023 May 05, 2023	BUY	$283.23 - $323.1 $38.8 Million - $44.3 Million	137,127 Added 34.14%	538,839 $170 Million
Q4 2022 Feb 10, 2023	BUY	$285.76 - $321.48 $3.96 Million - $4.45 Million	13,854 Added 3.57%	401,712 $116 Million
Q3 2022 Nov 01, 2022	BUY	$273.83 - $305.53 $104 Million - $116 Million	380,279 Added 5017.54%	387,858 $112 Million
Q2 2022 Aug 03, 2022	BUY	$234.96 - $292.55 $633,452 - $788,714	2,696 Added 55.21%	7,579 $2.14 Million
Q1 2022 May 13, 2022	BUY	$221.42 - $260.97 $677,988 - $799,090	3,062 Added 168.15%	4,883 $1.27 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $303,041 - $382,546	1,712 Added 1570.64%	1,821 $400,000
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $7,074 - $7,916	-39 Reduced 26.35%	109 $20,000
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $3,562 - $4,200	-19 Reduced 11.38%	148 $30,000
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $7,038 - $8,204	34 Added 25.56%	167 $36,000
Q4 2020 Feb 10, 2021	SELL	$207.01 - $276.09 $4,554 - $6,073	-22 Reduced 14.19%	133 $31,000
Q3 2020 Nov 13, 2020	SELL	$255.65 - $303.1 $39,370 - $46,677	-154 Reduced 49.84%	155 $42,000
Q2 2020 Aug 11, 2020	BUY	$225.48 - $295.8 $54,340 - $71,287	241 Added 354.41%	309 $90,000
Q1 2020 May 12, 2020	SELL	$199.77 - $247.81 $998 - $1,239	-5 Reduced 6.85%	68 $16,000
Q4 2019 Feb 11, 2020	BUY	$166.71 - $223.91 $12,169 - $16,345	73 New	73 $16,000
Q4 2018 Feb 13, 2019	SELL	$151.91 - $192.21 $446,615 - $565,097	-2,940 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$167.73 - $192.74 $14,760 - $16,961	-88 Reduced 2.91%	2,940 $567,000
Q2 2018 Aug 01, 2018	SELL	$145.72 - $169.96 $16,466 - $19,205	-113 Reduced 3.6%	3,028 $515,000
Q1 2018 May 16, 2018	SELL	$151.6 - $177.13 $2.13 Million - $2.49 Million	-14,041 Reduced 81.72%	3,141 $512,000
Q4 2017 Feb 13, 2018	BUY	$137.28 - $155.55 $2.35 Million - $2.67 Million	17,134 Added 35695.83%	17,182 $2.58 Million
Q3 2017 Nov 08, 2017	BUY	$148.13 - $162.24 $5,480 - $6,002	37 Added 336.36%	48 $7,000
Q2 2017 Aug 15, 2017	SELL	N/A	-62 Reduced 84.93%	11 $1,000
Q4 2016 Sep 15, 2017	SELL	N/A	-40 Reduced 35.4%	73 $5,000
Q3 2016 Sep 15, 2017	BUY	N/A	112 Added 11200.0%	113 $10,000
Q1 2016 Sep 15, 2017	SELL	N/A	-43 Reduced 97.73%	1 $0
Q4 2015 Sep 15, 2017	BUY	N/A	44	44 $6,000

Others Institutions Holding VRTX

# of Institutions

1,833

Shares Held

233M

Call Options Held

1.38M

Put Options Held

1.08M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.

Account